A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
Key facts
- Who runs it
- GlaxoSmithKline
- Where
- Bristol, Charlotte, Elkridge, Hickory, Phoenix, Pittsburgh, Salt Lake City, and San Antonio, United StatesSee the 8 sitesAlso in 17 other countries, 87 sites
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 3,038 people, planned
- Started
- 10 Aug 2022
- Expected to end
- 23 Aug 2027
- Type of study
- Interventional, 4 groups
- Treatments tested
- HZ/su vaccine
- Record updated
- 18 January 2024
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Participants and participant's caregiver, who, in the opinion of the investigator, can and are willing to comply with the requirements of the protocol
- Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study-specific procedure
- Medically stable participants as established by medical history and clinical examination before entering into the study
- Participants who completed ZOSTER-049 study (following at least 1 dose of HZ/su in ZOSTER-006/022 studies)
Who cannot take part
- Any clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study; Prior/Concomitant therapy
- Previous vaccination against VZV or HZ and/or planned administration during the study of a VZV or HZ vaccine (including an investigational or non-registered vaccine other than HZ/su administered in studies ZOSTER-006/022 or ZOSTER-049); Prior/Concurrent clinical study experience
- Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device) for the prevention and/or treatment of HZ or VZV and which may have a possible activity against VZV
- Medical conditions
- Use of any investigational or non-registered product (drug, vaccine or medical device) for the treatment of HZ or Varicella Zoster Virus (VZV) infection at the time of enrolment or their planned use during the study period
Where in United States
Also in 17 other countries, 87 sites
- Bristol, TennesseeHospital not named in the registry
- Charlotte, North CarolinaHospital not named in the registry
- Elkridge, MarylandHospital not named in the registry
- Hickory, North CarolinaHospital not named in the registry
- Phoenix, ArizonaHospital not named in the registry
- Pittsburgh, PennsylvaniaHospital not named in the registry
- Salt Lake City, UtahHospital not named in the registry
- San Antonio, TexasHospital not named in the registry
About the trial
What the trial wants to find out
The purpose of the current ZOSTER-101 long-term follow-up (LTFU) study of ZOSTER-049 (NCT02723773) study, an extension of ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies, is to assess the long-term vaccine efficacy (VE) against Herpes Zoster (HZ) (approximately 11-15 years post primary vaccination in ZOSTER-006/022 studies), persistence of immunogenicity and safety of GSK's Herpes Zoster subunit (HZ/su) vaccine in older adults. The persistence of immunogenicity and safety of 1 or 2 additional doses (0, 2-month schedule) of HZ/su vaccine administered to a small group of participants in ZOSTER-049 study (approximately 5 years after the initial vaccination in ZOSTER-006/022 studies) will also be assessed.
The 4 groups in the trial
- LTFU GroupOther group
Participants who received at least one dose of the HZ/su vaccine in the ZOSTER-006/022 primary studies and are followed for long-term vaccine efficacy and safety in the current ZOSTER-101 study.
Treatment: HZ/su vaccine
- 1-Additional Dose GroupOther group
Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and one additional dose of the HZ/su vaccine in the ZOSTER-049 study and are followed for persistence of immunogenicity and safety in the current ZOSTER-101 study.
Treatment: HZ/su vaccine
- Revaccination GroupOther group
Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and two additional doses of the HZ/su vaccine in the ZOSTER-049 study and are followed for persistence of immunogenicity and safety in the current ZOSTER-101 study.
Treatment: HZ/su vaccine
- Control GroupOther group
Participants who received two doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and no additional doses of the HZ/su vaccine in the ZOSTER-049 study, but who served as a control for the two groups that received 1 or 2 additional doses of HZ/su (1-Additional Dose and Revaccination groups). In the current ZOSTER-101 study, this Control group is used in the evaluation of the long-term vaccine efficacy, safety and as a control for persistence of immunogenicity to additional doses administered in ZOSTER-049 study.
Treatment: HZ/su vaccine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3b, Open-label, Multi-country, Multi-centre, Long-term Follow-up Study of ZOSTER-049 (Follow-up of ZOSTER-006/022 Studies) to Assess the Prophylactic Efficacy, Safety and Persistence of Immune Response of a Herpes Zoster Subunit Vaccine and Assessment of Persistence of Immune Response and Safety of 1 or 2 Additional Doses Administered in ZOSTER-049 in 2 Subgroups of Older Adults
- Record updated
- 18 January 2024